title: Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
abstract: We investigated the efficiency of nasal drug administration as a new non-invasive treatment strategy for MS. Glatiramer Acetate (GA) and GA-Cannabidiol (CBD) combination administered in nasal delivery system (NDS) resulted in a statistically significant decrease of clinical scores and inflammatory cytokine expression in experimental autoimmune encephalomyelitis (EAE) mice. Even a suboptimal dose of Prednisolone in NDS was effective in preventing the clinical signs of the disease. Neuron regeneration was observed in the hippocampus of EAE mice treated with GA-CBD in NDS. This work shows that nasal administration improved drug efficiency and stimulates further research for a non-invasive strategy for MS.
authors.affiliation: Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
authors.forename: Shaher
authors.initials: S
authors.lastname: Duchi
authors.forename: Haim
authors.initials: H
authors.lastname: Ovadia
authors.forename: Elka
authors.initials: E
authors.lastname: Touitou
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D002185:Cannabidiol / Q000008:administration & dosage*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D000068717:Glatiramer Acetate; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D009103:Multiple Sclerosis / Q000188:drug therapy; D009416:Nerve Regeneration / Q000187:drug effects; D010455:Peptides / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D010455:Peptides; D002185:Cannabidiol; D000068717:Glatiramer Acetate